+ Follow BERGAMO NEPHROLOGIC DIABETES COMPLICATION TRIAL Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 280937
[Title] => Combination drug delays onset of kidney disease
[Summary] => The antihypertensive pill containing an angiotensin-converting enzyme inhibitor and a non-dihydropryridine calcium channel blocker has been shown to reduce the incidence of microalbuminuria when compared with standard treatment, according to a study published recently in the New England Journal of Medicine.
Microalbuminuria, or small amounts of protein in the urine, is an early indicator of kidney disease and has been associated with an increased risk of cardiovascular problems.
[DatePublished] => 2005-06-09 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 274758
[Title] => Combination antihypertensive can delay early sign of kidney disease, trial shows
[Summary] => One of the most common complications of type 2 (adult onset) diabetes is a type of kidney disease known as diabetic nephropathy, a condition where the kidneys become less and less efficient in eliminating toxins from the body in the urine.
A recent study has demonstrated that a combination of trandolapril, an angiotensin-converting enzyme (ACE) inhibitor, and verapamil, a calcium channel blocker, reduced the incidence of protein in the urine or microalbuminuria, an early indicator of kidney disease, compared with placebo (sugar pill).
[DatePublished] => 2005-04-21 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
BERGAMO NEPHROLOGIC DIABETES COMPLICATION TRIAL
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 280937
[Title] => Combination drug delays onset of kidney disease
[Summary] => The antihypertensive pill containing an angiotensin-converting enzyme inhibitor and a non-dihydropryridine calcium channel blocker has been shown to reduce the incidence of microalbuminuria when compared with standard treatment, according to a study published recently in the New England Journal of Medicine.
Microalbuminuria, or small amounts of protein in the urine, is an early indicator of kidney disease and has been associated with an increased risk of cardiovascular problems.
[DatePublished] => 2005-06-09 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 274758
[Title] => Combination antihypertensive can delay early sign of kidney disease, trial shows
[Summary] => One of the most common complications of type 2 (adult onset) diabetes is a type of kidney disease known as diabetic nephropathy, a condition where the kidneys become less and less efficient in eliminating toxins from the body in the urine.
A recent study has demonstrated that a combination of trandolapril, an angiotensin-converting enzyme (ACE) inhibitor, and verapamil, a calcium channel blocker, reduced the incidence of protein in the urine or microalbuminuria, an early indicator of kidney disease, compared with placebo (sugar pill).
[DatePublished] => 2005-04-21 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
